(Q44712404)

5 December 2017

Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy (English)

1 reference

5 December 2017

1 reference

Thilo Dörk

17

0 references

Natalia V. Bogdanova

3

object named as

Natalia Bogdanova

1 reference

5 December 2017

7

Peter Schürmann

1 reference

5 December 2017

13

Peter Hillemanns

1 reference

5 December 2017

12

Michael Bremer

1 reference

5 December 2017

Andreas Meyer

1

1 reference

5 December 2017

Irina Coinac

2

1 reference

5 December 2017

Natalia Dubrowinskaja

4

1 reference

5 December 2017

Nurzhan Turmanov

5

1 reference

5 December 2017

Sabine Haubold

6

1 reference

5 December 2017

Florian Imkamp

8

1 reference

5 December 2017

Christoph von Klot

9

1 reference

5 December 2017

Axel S Merseburger

10

1 reference

5 December 2017

Stefan Machtens

11

1 reference

5 December 2017

Markus A Kuczyk

14

1 reference

5 December 2017

Johann H Karstens

15

1 reference

5 December 2017

Jürgen Serth

16

1 reference

5 December 2017

10 March 2011

1 reference

5 December 2017

1 reference

5 December 2017

31

1 reference

5 December 2017

1

1 reference

5 December 2017

74-81

1 reference

The complex genetic epidemiology of prostate cancer

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Prostate cancer genomics: towards a new understanding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Nucleic acid-based marker approaches to urologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Mutations in CHEK2 associated with prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

CHEK2 variants associate with hereditary prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

NBS1 is a prostate cancer susceptibility gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Long-range enhancers on 8q24 regulate c-Myc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Expression of Bcl-2 family member Bid in normal and malignant tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Regulation of prostate cancer progression by galectin-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Cell death: critical control points

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Apoptosis in cancer--implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Live or let die: the cell's response to p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Apoptosis and genomic instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Tumour suppression by p53: a role for the DNA damage response?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Investigation of the proapoptotic BCL-2 family member bid on the crossroad of the DNA damage response and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

The Bcl2 family: regulators of the cellular life-or-death switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

On the role of galectin-3 in cancer apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

The RASSF1A tumor suppressor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Initiator caspases in apoptosis signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Ways of dying: multiple pathways to apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Caspases: pharmacological manipulation of cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

ATM missense variant P1054R predisposes to prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Association of chromosomal locus 8q24 and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

A common coding variant in CASP8 is associated with breast cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

ATM polymorphisms as risk factors for prostate cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Risk of cancer by ATM missense mutations in the general population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.011

10.1016/J.UROLONC.2010.09.011

7 January 2021

Identifiers

DOI

1 reference

5 December 2017

1 reference